A transfer learning framework to elucidate the clinical relevance of altered proximal tubule cell states in kidney disease
David Legouis,
Anna Rinaldi,
Daniele Malpetti,
Gregoire Arnoux,
Thomas Verissimo,
Anna Faivre,
Francesca Mangili,
Andrea Rinaldi,
Lorenzo Ruinelli,
Jerome Pugin,
Solange Moll,
Luca Clivio,
Marco Bolis,
Sophie de Seigneux,
Laura Azzimonti,
Pietro E. Cippà
Affiliations
David Legouis
Division of Intensive Care, Department of Acute Medicine, University Hospital of Geneva, 1205 Geneva, Switzerland; Laboratory of Nephrology, Department of Medicine and Cell Physiology, University Hospital and University of Geneva, 1205 Geneva, Switzerland
Anna Rinaldi
Laboratories for Translational Research, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Division of Nephrology, Department of Medicine, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland
Daniele Malpetti
Istituto Dalle Molle di Studi sull'Intelligenza Artificiale (IDSIA), USI/SUPSI, Lugano, Switzerland
Gregoire Arnoux
Laboratory of Nephrology, Department of Medicine and Cell Physiology, University Hospital and University of Geneva, 1205 Geneva, Switzerland
Thomas Verissimo
Laboratory of Nephrology, Department of Medicine and Cell Physiology, University Hospital and University of Geneva, 1205 Geneva, Switzerland
Anna Faivre
Laboratory of Nephrology, Department of Medicine and Cell Physiology, University Hospital and University of Geneva, 1205 Geneva, Switzerland; Division of Nephrology, Department of Medicine, University Hospital of Geneva, 1205 Geneva, Switzerland
Francesca Mangili
Istituto Dalle Molle di Studi sull'Intelligenza Artificiale (IDSIA), USI/SUPSI, Lugano, Switzerland
Andrea Rinaldi
Institute of Oncological Research, 6500 Bellinzona, Switzerland
Lorenzo Ruinelli
Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland
Jerome Pugin
Division of Intensive Care, Department of Acute Medicine, University Hospital of Geneva, 1205 Geneva, Switzerland
Solange Moll
Division of Pathology, Department of Diagnostic, University Hospital of Geneva, 1205 Geneva, Switzerland
Luca Clivio
Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland
Marco Bolis
Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland; Laboratory of Computational Oncology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
Sophie de Seigneux
Laboratory of Nephrology, Department of Medicine and Cell Physiology, University Hospital and University of Geneva, 1205 Geneva, Switzerland; Division of Nephrology, Department of Medicine, University Hospital of Geneva, 1205 Geneva, Switzerland
Laura Azzimonti
Istituto Dalle Molle di Studi sull'Intelligenza Artificiale (IDSIA), USI/SUPSI, Lugano, Switzerland
Pietro E. Cippà
Laboratories for Translational Research, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Division of Nephrology, Department of Medicine, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland; Corresponding author
Summary: The application of single-cell technologies in clinical nephrology remains elusive. We generated an atlas of transcriptionally defined cell types and cell states of human kidney disease by integrating single-cell signatures reported in the literature with newly generated signatures obtained from 5 patients with acute kidney injury. We used this information to develop kidney-specific cell-level information ExtractoR (K-CLIER), a transfer learning approach specifically tailored to evaluate the role of cell types/states on bulk RNAseq data. We validated the K-CLIER as a reliable computational framework to obtain a dimensionality reduction and to link clinical data with single-cell signatures. By applying K-CLIER on cohorts of patients with different kidney diseases, we identified the most relevant cell types associated with fibrosis and disease progression. This analysis highlighted the central role of altered proximal tubule cells in chronic kidney disease. Our study introduces a new strategy to exploit the power of single-cell technologies toward clinical applications.